MMNFQ (MedMen Enterprises) Operating Income: $-29.3 Mil (TTM As of Mar. 2023)


What is MedMen Enterprises Operating Income?

MedMen Enterprises MMNFQ -90.00% Operating Income is $-29.3 Mil as of Mar. 2023.

MedMen Enterprises's Operating Income for the three months ended in Mar. 2023 was $-10.3 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2023 was $-29.3 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. MedMen Enterprises's Operating Income for the three months ended in Mar. 2023 was $-10.3 Mil. MedMen Enterprises's Revenue for the three months ended in Mar. 2023 was $27.2 Mil. Therefore, MedMen Enterprises's Operating Margin % for the quarter that ended in Mar. 2023 was -37.73%.

MedMen Enterprises's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MedMen Enterprises's annualized ROC % for the quarter that ended in Mar. 2023 was -9.35%. MedMen Enterprises's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -117.09%.

MedMen Enterprises  (OTCPK:MMNFQ) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MedMen Enterprises's annualized ROC % for the quarter that ended in Mar. 2023 is calculated as:

ROC % (Q: Mar. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Mar. 2023 ))/ count )
=-41.092 * ( 1 - 14.67% )/( (266.076 + 484.09)/ 2 )
=-35.0638036/375.083
=-9.35 %

where

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=238.475 - 109.832 - ( 15.605 - max(0, 237.644 - 100.211+15.605))
=266.076

Invested Capital(Q: Mar. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=215.587 - 114.701 - ( 7.626 - max(0, 474.281 - 91.077+7.626))
=484.09

Note: The Operating Income data used here is four times the quarterly (Mar. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

MedMen Enterprises's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Mar. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-99.744/( ( (91.921 + max(-82.052, 0)) + (78.457 + max(-79.06, 0)) )/ 2 )
=-99.744/( ( 91.921 + 78.457 )/ 2 )
=-99.744/85.189
=-117.09 %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.416 + 13.675 + 54.015) - (109.832 + 0.567 + 44.759)
=-82.052

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.862 + 14.669 + 64.92) - (114.701 + 0.567 + 47.243)
=-79.06

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

MedMen Enterprises's Operating Margin % for the quarter that ended in Mar. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2023 )/Revenue (Q: Mar. 2023 )
=-10.273/27.225
=-37.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

MedMen Enterprises Operating Income Related Terms

MedMen Enterprises Operating Income Historical Data

* Premium members only.

The historical data trend for MedMen Enterprises's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedMen Enterprises Operating Income Chart

MedMen Enterprises Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -90.10 -233.50 -186.43 -75.53 -61.30

MedMen Enterprises Quarterly Data
Apr18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.56 -7.24 -5.78 -6.01 -10.27

MedMen Enterprises Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of $-29.3 Mil mean?
MedMen Enterprises (MMNFQ) has a Operating Income of $-29.3 Mil as of Mar. 2023. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on MedMen Enterprises and its competitors.
Is MedMen Enterprises' Operating Income too high?
MedMen Enterprises' current Operating Income is $-29.3 Mil.
How does MedMen Enterprises' Operating Income compare to ZTS and VTRS?
MedMen Enterprises' Operating Income of $-29.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Drug Manufacturers company?
A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on MedMen Enterprises and its competitors. MedMen Enterprises's current Operating Income is $-29.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedMen Enterprises stock overvalued right now?
MedMen Enterprises (MMNFQ) has a current Operating Income of $-29.3 Mil. The current Operating Income is $-29.3 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For MedMen Enterprises (MMNFQ), the current Operating Income is $-29.3 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedMen Enterprises Business Description

Address 8740 S Sepulveda Boulevard, Suite 105, Los Angeles, CA, USA, 90045
MedMen Enterprises Inc is a American cannabis company dedicated to improving life with Cannabis for All. With operations across the United States in California, Nevada, Illinois, Arizona, Massachusetts, and New York, the company has MedMen and LuxLyte brands offering cannabis in consumer-preferred product forms for medical and recreational use. It produces and curates the consumer product assortment for retail operations in its local communities, and drives consumer loyalty with service and engaging in-store experience, combined with reward, delivery, and e-commerce programs.